BioLineRx’s Skin Lesion Removal Treatment Submitted for CE Mark

Israel-based BioLineRx’s business partner, Omega Pharma, has submitted an application for CE mark designation for the BL-5010, a nonsurgical approach to removing skin lesions.

The treatment offers an alternative to painful, invasive and costly removal techniques, such as cryotherapy, laser treatment and surgery, eliminating the need for anesthesia and bandaging. It also reduces the risk of infection.

The European Commission has classified the BL-5010 as a Class 2a medical device. The product was evaluated in clinical studies for the removal of seborrheic keratosis and other skin lesions, the company said. — Michael Cipriano